Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVD 1902 is a live attenuated oral vaccine candidate against Salmonella enterica serovar Paratyphi A (S. Paratyphi A), which causes paratyphoid fever. It was constructed from wild-type parent strain S. Paratyphi A strain ATCC 9150 by deleting the guaBA chromosomal operon (involved in guanine nucleotide biosynthesis) and the clpX gene (encoding a chaperone ATPase). The clpX mutation results in hyperexpression of flagella and serves as a second attenuating mutation to minimize the risk of reversion to full virulence. The vaccine is designed to stimulate both local protective immune responses along the intestinal surface and systemic immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cvd 1902.